Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results 0 20.12.2024 20:00 New York Post Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
